{
    "root": "1bfd9b13-808d-447f-a969-6019b18e60fc",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": {
        "text": "Depakote",
        "suffix": {
            "text": "ER"
        }
    },
    "value": "20250501",
    "ingredients": [
        {
            "name": "DIVALPROEX SODIUM",
            "code": "644VL95AO6"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "POTASSIUM SORBATE",
            "code": "1VPU26JZZ4"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "FD&C BLUE NO. 1",
            "code": "H3R47K3TBD"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "TRIACETIN",
            "code": "XHX3C3X673"
        },
        {
            "name": "LACTOSE, UNSPECIFIED FORM",
            "code": "J2B2A4N98G"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        },
        {
            "name": "POLYDEXTROSE",
            "code": "VH2XOU12IE"
        }
    ],
    "indications": "depakote er indicated : acute treatment manic mixed episodes associated bipolar disorder , without psychotic features ( 1.1 ) monotherapy adjunctive therapy complex partial seizures simple complex absence seizures ; adjunctive therapy patients multiple seizure types include absence seizures ( 1.2 ) prophylaxis migraine headaches ( 1.3 )",
    "contraindications": "depakote er extended-release product intended once-a-day oral . depakote er tablets swallowed whole crushed chewed .",
    "warningsAndPrecautions": "depakote er 250 mg available white ovaloid tablets containing divalproex sodium equivalent 250 mg valproic acid tablet following package sizes : bottles 100 , tablets “ ” logo code hf – ndc 0074-3826-13 bottles 100 , tablets code hf – ndc 0074-7401-13 depakote er 500 mg available gray ovaloid tablets containing divalproex sodium equivalent 500 mg valproic acid tablet following packaging sizes : bottles 100 , tablets “ ” logo code hc – ndc 0074-7126-13 bottles 100 , tablets code hc – ndc 0074-7402-13 bottles 500 , tablets “ ” logo code hc – ndc 0074-7126-53 unit dose packages 100 , tablets “ ” logo code hc – ndc 0074-7126-11 recommended storage : store tablets 25°c ( 77°f ) ; excursions permitted 15-30°c ( 59-86°f ) [ usp controlled room temperature ] .",
    "adverseReactions": "depakote er contraindicated patients : • hepatic disease significant hepatic dysfunction [ ( 5.1 ) ] . • known mitochondrial disorders caused mutations mitochondrial dna polymerase γ ( polg ; e.g . , alpers-huttenlocher syndrome ) children two years age suspected polg-related disorder [ ( 5.1 ) ] . • known hypersensitivity divalproex sodium , sodium valproate , valproic acid . included multiorgan hypersensitivity , serious dermatologic , angioedema [ ( 5.12 , 5.13 , 5.14 ) ] . • known urea cycle disorders [ ( 5.6 ) ] . • treated prophylaxis migraine headaches : pregnant women childbearing potential using effective contraception [ ( 5.2 , 5.3 , 5.4 ) ( 8.1 ) ] .",
    "indications_original": "Depakote ER is indicated for: Acute treatment of manic or mixed episodes associated with bipolar disorder, with or without psychotic features ( 1.1 ) Monotherapy and adjunctive therapy of complex partial seizures and simple and complex absence seizures; adjunctive therapy in patients with multiple seizure types that include absence seizures ( 1.2 ) Prophylaxis of migraine headaches ( 1.3 )",
    "contraindications_original": "Depakote ER is an extended-release product intended for once-a-day oral administration. Depakote ER tablets should be swallowed whole and should not be crushed or chewed.",
    "warningsAndPrecautions_original": "Depakote ER 250 mg is available as white ovaloid tablets containing divalproex sodium equivalent to 250 mg of valproic acid in each tablet in the following package sizes: \n                  \n                     Bottles of 100, tablets with the “a” logo and the code HF – NDC 0074-3826-13\n                     \n                     Bottles of 100, tablets with the code HF – NDC 0074-7401-13\n                  \n                  Depakote ER 500 mg is available as gray ovaloid tablets containing divalproex sodium equivalent to 500 mg of valproic acid in each tablet in the following packaging sizes: \n                  \n                     Bottles of 100, tablets with the “a” logo and the code HC – NDC 0074-7126-13\n                     \n                     Bottles of 100, tablets with the code HC – NDC 0074-7402-13\n                     \n                     Bottles of 500, tablets with the “a” logo and the code HC – NDC 0074-7126-53\n                     \n                     Unit Dose Packages of 100, tablets with the “a” logo and the code HC – NDC 0074-7126-11\n                  \n                  Recommended Storage: Store tablets at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature].",
    "adverseReactions_original": "Depakote ER is contraindicated in patients: \n                    • with hepatic disease or significant hepatic dysfunction [see Warnings and Precautions \n                     (\n                     \n                        5.1\n                     \n                     )\n                     ].\n                  \n                    • known to have mitochondrial disorders caused by mutations in mitochondrial DNA polymerase γ (POLG; e.g., Alpers-Huttenlocher Syndrome) and children under two years of age who are suspected of having a POLG-related disorder [see Warnings and Precautions \n                     (\n                     \n                        5.1\n                     \n                     )\n                     ]. \n                  \n                       • with known hypersensitivity to  divalproex sodium, sodium valproate, or valproic acid. Reactions have included multiorgan hypersensitivity, serious dermatologic reactions, and angioedema [see Warnings and Precautions \n                        (\n                        \n                           5.12\n                        \n                        , \n                        \n                           5.13\n                        \n                        , \n                           5.14\n                        \n                        )\n                        ].\n                     \n                  \n                    • with known urea cycle disorders [see Warnings and Precautions \n                     (\n                     \n                        5.6\n                     \n                     )\n                     ].\n                  \n                    • being treated for prophylaxis of migraine headaches: who are pregnant or in women of childbearing potential who are not using effective contraception [see Warnings and Precautions \n                     (\n                     \n                        5.2\n                     \n                     , \n                     \n                        5.3\n                     \n                     , \n                     \n                        5.4\n                     \n                     )\n                      and Use in Specific Populations \n                     (\n                     \n                        8.1\n                     \n                     )\n                     ]."
}